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Introduction 
The reduction of genetic disorders remains an important goal for both veterinarians and breeders. An important step in this process is 
to evaluate the prevalence of disorders and mutant alleles in the population. This study reports on the prevalence of mutant alleles 
from 9 canine genetic disorders that influence the neuronal and/or musculoskeletal system (Table 1). 
Materials and methods 
Blood samples (K3EDTA) were collected from Belgian, Dutch and German dogs. Irrespective of breed, samples (n = 476, 70 breeds) 
were tested for the presence of mutations. Genotyping was conducted using Kompetitive Allele Specifc PCR (KASP).  
Disorder Gene Similar human disease 
Hip dysplasia (HD) Fibrillin 2 (FBN2) Congenital Contractural Arachnodactyly 
Degenerative myelopathy (DM) Superoxide dismutase 1 (SOD1) Amyotrophic lateral sclerosis 
Exercise-induced collapse (EIC) Dynamin 1 (DNM1) - 
Neuronal ceroid lipofuscinosis 4A (NCL) Arylsulfatase G (ARSG) Kufs disease 
Centronuclear myopathy (HMLR) Protein tyrosine phosphatase-like (PTPLA) Human centronuclear myopathy 
Mucopolysaccharidosis VII (MPS VII) Beta-glucuronidase (GUSB) Mucopolysaccharidosis VII 
Myotonia congenita (MG) Chloride channel, voltage sensitive 1 (CLCN1) Generalized myotonia (Beckers disease) 
Gangliosidosis (GM1) Beta-galactosidase (GLB1)  Gangliosidosis 
Muscular dystrophy (Duchenne) (GRMD) Dystrophin (DMD)  Duchenne Muscular Dystrophy 
Results  
For 5 out of 9 disorders (HMLR, MPS VII, MG, GM1, GRMD), no 
genetic variation was found in any sample from all breeds.  
For the other 4 disorders (HD, DM, EIC, NCL), genetic variation 
was observed in a wide variety of breeds.  
For HD, DM, EIC and NCL the mutant allele was detected for the 
first time in respectively 43, 13, 2 and 1 breeds.  
Surprisingly, mutant alleles for 3 autosomal recessive disorders 
(DM, EIC and NCL) were found in 9, 2 and 1 breeds respectively 
where the disorder has not (yet?) been reported clinically.  
The mutant alleles for HD and EIC were also identified in mixed 
dog breeds. Breed specific prevalence of the mutant allele can be 
found in Figure 1.  
Conclusion 
Veterinarians and dog breeders should be aware that mutations might be present in breeds where a disorder has not been 
reported.  If dogs from non-suspected breeds show comparable symptoms, they can be tested and results should be 
reported. 
Figure 1. Mutant allele frequency for hip dysplasia (HD), degenerative myelopathy 
(DM), exercise-induced collapse (EIC) and neuronal ceroid lipofuscinosis (NCL). 
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Table 1. Overview of 9 disorders tested with the gene where the mutation was identified and the animal model for similar human diseases. 
